[
  {
    "ts": null,
    "headline": "Emmecell Appoints Ramin Valian as Chief Executive Officer to Advance Magnetic Cell Delivery Platform",
    "summary": "MENLO PARK, Calif., January 16, 2026--Emmecell announces the appointment of ophthalmology leader Ramin Valian as CEO.",
    "url": "https://finnhub.io/api/news?id=2fa5e2aa0c4ac6ecab8867dd072b729a8d22d06b542891341c1ad4ca827445df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768592880,
      "headline": "Emmecell Appoints Ramin Valian as Chief Executive Officer to Advance Magnetic Cell Delivery Platform",
      "id": 138155353,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "MENLO PARK, Calif., January 16, 2026--Emmecell announces the appointment of ophthalmology leader Ramin Valian as CEO.",
      "url": "https://finnhub.io/api/news?id=2fa5e2aa0c4ac6ecab8867dd072b729a8d22d06b542891341c1ad4ca827445df"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
    "summary": "AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])*. Improvements were observed in complete response rates (CRR), durat",
    "url": "https://finnhub.io/api/news?id=4f51da30e4cbd7a41e182fcd608706c5aaf4b89b086fbe3e8e7229290768650e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768588980,
      "headline": "AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
      "id": 138155354,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])*. Improvements were observed in complete response rates (CRR), durat",
      "url": "https://finnhub.io/api/news?id=4f51da30e4cbd7a41e182fcd608706c5aaf4b89b086fbe3e8e7229290768650e"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency",
    "summary": "AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology pipeline.",
    "url": "https://finnhub.io/api/news?id=6eec269a780b992e9ff22b62296f1dde50dd508b49e2c088df3adf406bd0a3f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768571620,
      "headline": "JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency",
      "id": 138151714,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology pipeline.",
      "url": "https://finnhub.io/api/news?id=6eec269a780b992e9ff22b62296f1dde50dd508b49e2c088df3adf406bd0a3f2"
    }
  },
  {
    "ts": null,
    "headline": "Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data",
    "summary": "Ocugen, Inc. gene therapy outlook: key 2026 catalysts, Phase 2/3 eye-disease data, BLA plans to 2028, and risks. Click for this OCGN update.",
    "url": "https://finnhub.io/api/news?id=3a4f532118ffd7eac05a221904dad80cd2cb3c0e196b8e53fd28359fd7d53728",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768566535,
      "headline": "Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data",
      "id": 138153628,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1306234498/image_1306234498.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Ocugen, Inc. gene therapy outlook: key 2026 catalysts, Phase 2/3 eye-disease data, BLA plans to 2028, and risks. Click for this OCGN update.",
      "url": "https://finnhub.io/api/news?id=3a4f532118ffd7eac05a221904dad80cd2cb3c0e196b8e53fd28359fd7d53728"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc.'s (NYSE:ABBV) institutional investors lost 3.3% last week but have benefitted from longer-term gains",
    "summary": "Key Insights Institutions' substantial holdings in AbbVie implies that they have significant influence over the...",
    "url": "https://finnhub.io/api/news?id=6600ee6eec918eb65d7841523891ad0a507293eef015f2b021f5c5a602183fab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768561220,
      "headline": "AbbVie Inc.'s (NYSE:ABBV) institutional investors lost 3.3% last week but have benefitted from longer-term gains",
      "id": 138150986,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Key Insights Institutions' substantial holdings in AbbVie implies that they have significant influence over the...",
      "url": "https://finnhub.io/api/news?id=6600ee6eec918eb65d7841523891ad0a507293eef015f2b021f5c5a602183fab"
    }
  }
]